Research
Hormonal
Dietary restriction stimulates neurogenesis (the generation of new neurons) in the adult hippocampus, primarily by enhancing the survival of newly generated cells via BDNF, rather than increasing the proliferation rate of stem cells.
Fasting or caloric restriction helps the brain create and keep new neurons in the hippocampus, which is linked to better memory and learning. This happens because the new neurons are more likely to survive, not because they are created faster. This benefit depends on having normal levels of BDNF.
GoodSupportsHIGH confidence
There was no difference in BrdU-labeled cells between DR and control animals at the 1-day time point indicating that DR does not affect the proliferation rate of the neural stem cells. However, there was a significant increase in the number of BrdU-positive cells remaining at the 3- and 4-week time points in the animals on DR, suggesting that DR promotes the survival of newly generated neural cells.
Why this rating
Supported by animal studies using BrdU labeling and BDNF knockout models.
Source
Meal size and frequency affect neuronal plasticity and vulnerability to disease: cellular and molecular mechanisms
Mark P. Mattson et al. · Journal of Neurochemistry · 2003
DOI 10.1046/j.1471-4159.2003.01586.x
narrative_reviewCited 289×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
- Dietary restriction (DR), including caloric restriction and intermittent fasting, extends lifespan and protects against neurodegenerative diseases (Alzheimer's, Parkinson's, stroke) by inducing a cellular stress response that upregulates neurotrophic factors (BDNF) and protein chaperones (HSP-70).Good
- Dietary restriction does not protect against all neurodegenerative conditions; specifically, it fails to protect and may accelerate disease progression in models of ALS caused by Cu/Zn-SOD mutations.Moderate
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →